ArticleFrontiers in pharmacology2026
Extracellular vesicle-like particles from
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Plant-derived extracellular vesicle-like particles (EVLPs) are emerging as natural, orally deliverable nanomaterials, but their antitumor activity and mitochondrial mechanisms in non-small cell lung cancer (NSCLC) remain insufficiently defined. Methods: Taraxacum mongolicum-derived EVLPs (TM-EVLPs) were isolated by enzymatic digestion and differential ultracentrifugation and characterized by nanoparticle tracking analysis, transmission electron microscopy, and protein profiling. Cellular uptake and antitumor effects were evaluated in A549 and H1975 cells using proliferation, migration, invasion, epithelial-mesenchymal transition, and mitochondrial function assays. In vivo efficacy and safety were assessed in an A549 xenograft model after oral TM-EVLP administration. Results: DiI-labeled TM-EVLPs showed clear cell-associated signals after incubation and washing. TM-EVLPs inhibited NSCLC cell viability, DNA synthesis, clonogenicity, migration, and invasion, with more consistent effects at higher concentrations, and increased E-cadherin but decreased N-cadherin expression. TM-EVLP treatment was associated with mitochondrial membrane potential depolarization, increased mitochondrial reactive oxygen species, reduced ATP production, disrupted cristae ultrastructure, and decreased oxidative phosphorylation complex subunits. In xenograft-bearing mice, oral TM-EVLPs (5-20 mg/kg, 15 days) reduced tumor growth, decreased Ki-67 and PCNA staining, increased TUNEL positivity, recapitulated mitochondrial impairment in tumors, and caused no overt histological injury in major organs. Discussion: TM-EVLPs suppress NSCLC malignant phenotypes in association with constrained mitochondrial bioenergetics and increased oxidative stress, supporting a mitochondria-centered stress-linked working model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.